Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aminosalicylic Acid

FDA-approved product (tablet, oral), marketed as P.a.s. Sodium, Parasal Sodium, Sodium Aminosalicylate and 7 more.

Registered studies
1
Lab records
4
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Aminosalicylic Acid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminosalicylic acid and derivatives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AA01; WHO ATC J04AA02; WHO ATC J04AA03

Repurposing investigation

Aminosalicylic Acid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA12.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

1registered study names this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 4 lab records
Open Aminosalicylic Acid in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aminosalicylic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT03830671 · start 2019-03-08

    Registered record
    Registry ID
    NCT03830671
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    18-month regimen containing 6 anti-TB drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-08
    Completion
    2022-06-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    Intervention18-month regimen containing 6 anti-TB drugs
    PhasePhase 4
    Registry statusCompleted